Replies to post #62055 on NorthWest Biotherapeutics Inc (NWBO)

[vator]

"
Canadian drug developer Aeterna Zentaris has been forced to discontinue its Phase III clinical trial of blood cancer drug perifosine after the Data Safety Monitoring Board (DSMB) said it was "highly unlikely the study would achieve a significant difference in its primary endpoint".

Right. Shows how long you have been in the business. This is what I was talking about.

[Doktornolittle]

I think the cashless warrants that AEZS contracted were a scam, not simply a desperation move to finance. There is a difference.

NWBO could ultimately prove to have been a scam, but at this point I don't believe that is the case. I believe they really couldn't get other financing recently, or that possibly there was some deal made to offset some wrong doing on NWBO's part. That could be called a scam, but there is an issue of proportion here. Even if the warrants had been given away for free, what was the dilution? I'm not certain to be honest, but if it was about 6.6M shares then that was less than 7% dilution vs 1000% for AEZS, or was it 10,000%. Either way... AEZS'd dilution was 2 or 3 orders of magnitude more dilution than NWBO's recent dilution... Not belonging in the same conversation.